AGP Executive Report
Last update: 7 hours agoBiotech & Drug Development: BioVie says it’s in active talks with the FDA to finalize Phase 3 design for bezisterim in Parkinson’s, with a plan that may enrich patients showing inflammation-linked benefit. Pharvaris reports positive topline results from CHAPTER-3 for deucrictibant XR to prevent hereditary angioedema attacks, setting up planned marketing submissions in 2027. Clinical Evidence & Patient Care: TYLENOL with Naproxen is backed by new Phase 3 data presented at PAINWeek, supporting an OTC non-opioid option for post-surgical pain. Healthcare Access & Workforce: West Virginia will distribute $2.4M in rural health funds to expand employer-based worksite clinics. Quincy Valley Medical Center says its new facility is driving higher outpatient and emergency volumes after a year. Health Tech & Infrastructure: Spain’s SETT invests €7.2M in Deneb Medical to accelerate robotic, AI-enabled precision spine surgery. A UK hospital estates team is shortlisted for sustainability awards after a major decarbonisation push. Business & Policy Watch: A Kansas hospital system warns more patients are becoming uninsured as ACA premium supports expire, raising pressure for affordable coverage options. Research & Investment: Cloverleaf Bio closes a $33M seed round to advance RNA-based cancer therapeutics; BrainChild Bio raises $116M Series A for CAR T work in pediatric brainstem tumors.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
